장기이식 거부반응과 자가면역질환 치료제로서의 CAR Treg 세포치료제의 가능성: Treg 세포치료제 임상시험 현황과 CAR T 세포치료제 허가 정보를 바탕으로 = Current Perspectives on Emerging CAR-Treg Cell Therapy: Based on Treg Cell Therapy in Clinical Trials and the Recent Approval of CAR-T Cell Therapy

다국어 초록 (Multilingual Abstract)

Regulatory T cells (Treg) naturally rein in immune attacks, and they can inhibit rejection of transplanted organs and even reverse the progression of autoimmune diseases in mice. The initial safety trials of Treg against graft-versus-host disease (GVHD) provided evidence that the adoptive transfer of Treg is safe and capable of limiting disease progression. Supported by such evidence, numerous clinical trials have been actively investigating the efficacy of Treg targeting autoimmune diseases, type I diabetes, and organ transplant rejection, including kidney and liver. The limited quantity of Treg cells harvested from peripheral blood and subsequent in vitro culture have posed a great challenge to large-scale clinical application of Treg; nevertheless, the concept of CAR (chimeric antigen receptor)-Treg has emerged as a potential resolution to the problem. Recently, two CAR-T therapies, tisagenlecleucel and axicabtagene ciloleucel, were approved by the US FDA for the treatment of refractory or recurrent acute lymhoblastic leukemia. This approval could serve as a guideline for the production protocols for other genetically engineered T cells for clinical use as well. The phase I and II clinical trials of these agents has demonstrated that genetically engineered and antigen-targeting T cells are safe and efficacious in humans. In conclusion, both the promising results of Treg cell therapy from the clinical studies and the recent FDA approval of CAR-T therapies are paving the way for CAR-Treg therapy in clinical use.

참고문헌 (Reference)

1 Bluestone JA, "Type 1 diabetes immunotherapy using polyclonal regulatory T cells" 7 : 315-, 2015

2 Di Ianni M, "Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation" 117 : 3921-3928, 2011

3 Niemann N, "Treg therapy in transplantation:how and when will we do it?" 2 : 233-241, 2015

4 Battaglia M, "Tr1cells : from discovery to their clinical application" 18 : 120-127, 2006

5 Brudno JN, "Toxicities of chimeric antigen receptor T cells : recognition and management" 127 : 3321-3330, 2016

6 Wojciechowski D, "Tofacitinib in kidney transplantation" 22 : 1193-1199, 2013

7 Gelson W, "The pattern of late mortality in liver transplant recipients in the United Kingdom" 91 : 1240-1244, 2011

8 Taylor PA, "The infusion of ex vivo activated and expanded CD4(+)CD25(+)immune regulatory cells inhibits graft-versus-host disease lethality" 99 : 3493-3499, 2002

9 Bennett CL, "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)is caused by mutations of FOXP3" 27 : 20-21, 2001

10 Nafady-Hego H, "The generation of donor-specific CD4+CD25++CD45RA+ naive regulatory T cells in operationally tolerant patients after pediatric living-donor liver transplantation" 90 : 1547-1555, 2010

11 Geissler EK, "The ONE Study compares cell therapy products in organ transplantation : introduction to a review series on suppressive monocyte-derived cells" 1 : 11-, 2012

12 Fransson M, "T regulatory cells lacking CD25 are increased in MS during relapse" 43 : 590-597, 2010

13 Euvrard S, "Skin cancers after organ transplantation" 348 : 1681-1691, 2003

14 Abboud R, "Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6therapy is safe and well tolerated" 22 : 1851-1860, 2016

15 Topp MS, "Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study" 16 : 57-66, 2015

16 Soltys KA, "SPLIT Research Group. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database" 7 : 2165-2171, 2007

17 Cho H, "Risk factors for graft failure and death following geriatric renal transplantation" 11 : e0153410-, 2016

18 Seino KI, "Requirement for natural killer T(NKT)cells in the induction of allograft tolerance" 98 : 2577-2581, 2001

19 Cobbold SP, "Regulatory cells and transplantation tolerance" 3 : a015545-, 2013

20 Tang Q, "Regulatory T-cell therapy in transplantation:moving to the clinic" 3 : a015552-, 2013

21 Edozie FC, "Regulatory T-cell therapy in the induction of transplant tolerance : the issue of subpopulations" 98 : 370-379, 2014

22 Sakaguchi S, "Regulatory T cells: how do they suppress immune responses?" 21 : 1105-1111, 2009

23 Edinger M, "Regulatory T cells in stem cell transplantation : strategies and first clinical experiences" 23 : 679-684, 2011

24 Haribhai D, "Regulatory T cells dynamically control the primary immune response to foreign antigen" 178 : 2961-2972, 2007

25 Sagoo P, "Regulatory T cells as therapeutic cells" 13 : 645-653, 2008

26 Chen Y, "Regulatory T cell clones induced by oral tolerance : suppression of autoimmune encephalomyelitis" 265 : 1237-1240, 1994

27 Haas J, "Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis" 35 : 3343-3352, 2005

28 Elinav E, "Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice" 134 : 2014-2024, 2008

29 Safinia N, "Promoting transplantation tolerance; adoptive regulatory T cell therapy" 172 : 158-168, 2013

30 Joffre O, "Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes" 14 : 88-92, 2008

31 Textor SC, "Posttransplantation hypertension related to calcineurin inhibitors" 6 : 521-530, 2000

32 Novartis, "Oncologic Drugs Advisory Committee Briefing Document: Tisagenlecleucel (CTL019)"

33 Nair S, "Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States" 35 : 105-109, 2002

34 Curotto de Lafaille MA, "Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?" 30 : 626-635, 2009

35 Meier-Kriesche HU, "Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?" 4 : 1289-1295, 2004

36 Pasquet L, "Long-term prevention of chronic allograft rejection by regulatory T-cell immunotherapy involves host Foxp3-expressing T cells" 121 : 4303-4310, 2013

37 Hoffmann P, "Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells" 104 : 895-903, 2004

38 Brunstein CG, "Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood : safety profile and detection kinetics" 117 : 1061-1070, 2011

39 Tsang JY, "Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+)regulatory T cells with indirect allospecificity and short term immunosuppression" 21 : 203-209, 2009

40 Chatenoud L, "In vivo cell activation following OKT3administration. Systemic cytokine release and modulation by corticosteroids" 49 : 697-702, 1990

41 Tang Q, "In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes" 199 : 1455-1465, 2004

42 Barrat FJ, "In vitro generation of interleukin 10-producing regulatory CD4(+)T cells is induced by immunosuppressive drugs and inhibited by T helper type 1(Th1)-and Th2-inducing cytokines" 195 : 603-616, 2002

43 Bacchetta R, "Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells" 5 : 16-, 2014

44 Sakaguchi S, "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases" 155 : 1151-1164, 1995

45 Zhang ZX, "Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression" 6 : 782-789, 2000

46 Levings MK, "IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells" 166 : 5530-5539, 2001

47 Trzonkowski P, "Hurdles in therapy with regulatory T cells" 7 : 304ps18-, 2015

48 Sagoo P, "Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells" 3 : 83ra42-, 2011

49 Juvet SC, "Harnessing regulatory T cells for clinical use in transplantation : the end of the beginning" 14 : 750-763, 2014

50 Gilliet M, "Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells" 195 : 695-704, 2002

51 Trzonkowski P, "First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells" 133 : 22-26, 2009

52 Gross G, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity" 86 : 10024-10028, 1989

53 Boardman DA, "Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection" 17 : 931-943, 2017

54 Davies JK, "Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation" 1 : 1ra3-, 2009

55 Veerapathran A, "Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly" 118 : 5671-5680, 2011

56 Morgan ME, "Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+regulatory T cells" 52 : 2212-2221, 2005

57 Hoffmann P, "Donor-type CD4(+)CD25(+)regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation" 196 : 389-399, 2002

58 Suntharalingam G, "Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412" 355 : 1018-1028, 2006

59 Kohm AP, "Cutting edge : CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis" 169 : 4712-4716, 2002

60 Tsang JY, "Conferring indirect allospecificity on CD4+CD25+Tregs by TCR gene transfer favors transplantation tolerance in mice" 118 : 3619-3628, 2008

61 Venken K, "Compromised CD4+ CD25(high)regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level" 123 : 79-89, 2008

62 Putnam AL, "Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation" 13 : 3010-3020, 2013

63 Ojo AO, "Chronic renal failure after transplantation of a nonrenal organ" 349 : 931-940, 2003

64 Grupp SA, "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia" 368 : 1509-1518, 2013

65 Ruella M, "Chimeric antigen receptor T cells for B cell neoplasms : choose the right CAR for you" 11 : 368-384, 2016

66 Geissler EK, "Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients" 18 : 408-415, 2013

67 Penn I, "Cancers complicating organ transplantation" 323 : 1767-1769, 1990

68 Kingsley CI, "CD25+CD4+regulatory T cells prevent graft rejection : CTLA-4-and IL-10-dependent immunoregulation of alloresponses" 168 : 1080-1086, 2002

69 Fransson M, "CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery" 9 : 112-, 2012

70 Cheadle EJ, "CAR T cells : driving the road from the laboratory to the clinic" 257 : 91-106, 2014

71 Lee K, "Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy" 14 : 27-38, 2014

72 Berenson GS, "Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy(The Bogalusa Heart Study)" 70 : 851-858, 1992

73 Boardman D, "Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?" 44 : 342-348, 2016

74 Mahmud N, "Antibody immunosuppressive therapy in solid-organ transplant : part I" 2 : 148-156, 2010

75 Theil A, "Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease" 17 : 473-486, 2015

76 The ONE Study, "A unified approach to evaluating cellular immunotherapy in solid organ transplantation" The ONE Study

77 Coombes JL, "A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism" 204 : 1757-1764, 2007